Alfred E. Mann Institute for Biomedical Engineerin - Los Angeles CA, US Gary Steven Lazar - Encino CA, US Doug Yin - Valencia CA, US
Assignee:
Alfred E. Mann Institute for Biomedical Engineering at the Univ. of Southern California - Los Angeles CA
International Classification:
A61N 1/05
US Classification:
607115
Abstract:
This disclosure relates to an in vivo treatment of a skin lesion of a mammal comprising application of electrical energy to the skin lesion in a form of electrical pulses. At least one electrical pulse is applied. The pulse duration may be at least 0.01 nanoseconds at the full-width-at-half-maximum. This treatment may at least prevent growth of the lesion.
Reduction of EMP2 expression and/or anti-EMP2 therapy reduces cancer stem cells in multiple types of cancer. For example, breast cancers stem cells were defined by the presence of HIF-1α, CD44 and ALDH. It is found that anti-EMP2 IgG1 can be used to reduce the numbers of cancer stem cells.
Reduction of EMP2 expression and/or anti-EMP2 therapy reduces cancer stem cells in multiple types of cancer. For example, breast cancers stem cells were defined by the presence of HIF-1α, CD44 and ALDH. It is found that anti-EMP2 IgG1 can be used to reduce the numbers of cancer stem cells.
Name / Title
Company / Classification
Phones & Addresses
Gary Lazar Managing Director California Technology Ventures